As bluebird projects more commercial demand, the biotech continues to seek cash
Bluebird reported that 17 people with sickle cell disease have started the process of receiving its gene therapy Lyfgenia.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
